SCHEMBL2361775

SCHEMBL2361775

CCN(CC)CCn1c2ccccc2c2cc(C(C)=O)c(O)cc21

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HIF1A Q16665 1/20 0.52
G6PD P11413 1/20 0.52
EGFR P00533 1/20 0.48
MAPT P10636 2/20 0.48
SLC6A4 P31645 2/20 0.46
SLC6A2 P23975 1/20 0.46
HRH1 P35367 1/20 0.46
TOP2A P11388 1/20 0.45
SMARCA2 P51531 2/20 0.44
NPC1 O15118 1/20 0.44
POLB P06746 1/20 0.44
GAA P10253 1/20 0.44
RAD52 P43351 1/20 0.44
RAB9A P51151 1/20 0.44
MEN1 O00255 2/20 0.44
KMT2A Q03164 2/20 0.44
CCR6 P51684 1/20 0.44
ALDH1A1 P00352 1/20 0.43
HPGD P15428 1/20 0.43
SMN1; SMN2 Q16637 3/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12608683 0.87 CNR2 (0.44) HIF1AG6PDEGFRMAPTPOLB
SCHEMBL2334457 0.79 POLB (0.63) HIF1AG6PDEGFRMAPTSLC6A4
SCHEMBL13418980 0.78 HIF1A (0.56) HIF1AG6PDEGFRMAPTSLC6A4
Diethylamine SCHEMBL2361776 0.78 NPSR1 (0.53) HIF1AMAPTPOLBRAB9AMEN1
SCHEMBL15848974 0.78 CNR2 (0.54) HIF1AG6PDEGFRMAPTSLC6A4
SCHEMBL13011521 0.77 ALDH1A1 (0.62) HIF1AG6PDEGFRMAPTSLC6A4
SCHEMBL14472124 0.76 PSEN1 (0.49) HIF1AG6PDEGFRMAPTSLC6A4
SCHEMBL12608665 0.76 CNR2 (0.45) HIF1AG6PDEGFRMAPTPOLB
SCHEMBL4727522 0.75 SLC6A4 (0.56) HIF1AEGFRSLC6A4SLC6A2HRH1
SCHEMBL12608660 0.74 CNR2 (0.43) HIF1AG6PDEGFRMAPTPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20190082845-A1 CARBAZOLE COMPOUNDS AND THERAPEUTIC USES OF THE COMPOUNDS INCURON INC (US) 2019-03-21 US disclosed
US-20190082845-A1 CARBAZOLE COMPOUNDS AND THERAPEUTIC USES OF THE COMPOUNDS INCURON INC (US) 2019-03-21 US disclosed
US-10137109-B2 Carbazole compounds and therapeutic uses of the compounds INCURON, INC. (US) 2018-11-27 US disclosed
US-20170165229-A1 CARBAZOLE COMPOUNDS AND THERAPEUTIC USES OF THE COMPOUNDS INCURON, INC. 2017-06-15 US disclosed
US-20170165229-A1 CARBAZOLE COMPOUNDS AND THERAPEUTIC USES OF THE COMPOUNDS INCURON, INC. 2017-06-15 US disclosed
US-20170165229-A1 CARBAZOLE COMPOUNDS AND THERAPEUTIC USES OF THE COMPOUNDS INCURON, INC. 2017-06-15 US disclosed
US-9566265-B2 Carbazole compounds and therapeutic uses of the compounds INCURON, LLC (US) 2017-02-14 US disclosed
US-9566265-B2 Carbazole compounds and therapeutic uses of the compounds INCURON, LLC (US) 2017-02-14 US disclosed
US-9566265-B2 Carbazole compounds and therapeutic uses of the compounds INCURON, LLC (US) 2017-02-14 US disclosed
US-20150342927-A1 CARBAZOLE COMPOUNDS AND THERAPEUTIC USES OF THE COMPOUNDS INCURON, INC. 2015-12-03 US disclosed
US-8765738-B2 Carbazole compounds and therapeutic uses of the compounds INCURON, LLC (US) 2014-07-01 US disclosed
US-8765738-B2 Carbazole compounds and therapeutic uses of the compounds INCURON, LLC (US) 2014-07-01 US disclosed
US-8765738-B2 Carbazole compounds and therapeutic uses of the compounds INCURON, LLC (US) 2014-07-01 US disclosed
EP-2356093-B1 Carbazole compounds and therapeutic uses of the compounds INCURON LLC (RU) 2013-01-09 EP disclosed
US-20110305661-A1 Carbazole Compounds and Therapeutic Uses of the Compounds INCURON, INC. 2011-12-15 US disclosed
US-20110305661-A1 Carbazole Compounds and Therapeutic Uses of the Compounds INCURON, INC. 2011-12-15 US disclosed
US-20110305661-A1 Carbazole Compounds and Therapeutic Uses of the Compounds INCURON, INC. 2011-12-15 US disclosed
EP-2356093-A1 Carbazole compounds and therapeutic uses of the compounds INCURON, LLC (RU) 2011-08-17 EP disclosed
WO-2010042445-A1 CARBAZOLE COMPOUNDS AND THERAPEUTIC USES OF THE COMPOUNDS CLEVELAND BIOLABS, INC. (US) 2010-04-15 WO disclosed
WO-2010042445-A1 CARBAZOLE COMPOUNDS AND THERAPEUTIC USES OF THE COMPOUNDS CLEVELAND BIOLABS, INC. (US) 2010-04-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170165229-A1 CARBAZOLE COMPOUNDS AND THERAPEUTIC USES OF THE COMPOUNDS MALT1, PAICS, BCL9 HIF1A 2320/4885G6PD 547/4885EGFR 2958/4885
US-20150342927-A1 CARBAZOLE COMPOUNDS AND THERAPEUTIC USES OF THE COMPOUNDS MALT1, PAICS, BCL9 HIF1A 2320/4885G6PD 547/4885EGFR 2958/4885
US-10137109-B2 Carbazole compounds and therapeutic uses of the compounds MALT1, PAICS, BCL9 HIF1A 2320/4885G6PD 547/4885EGFR 2958/4885
US-20110305661-A1 Carbazole Compounds and Therapeutic Uses of the Compounds MALT1, PAICS, TPMT HIF1A 2321/4885G6PD 436/4885EGFR 2791/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.